Advances in™ Beta-Thalassemia: The Evolving Therapeutic Landscape
January 21, 2022
January 21, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from Chiesi USA
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
This educational activity is directed toward hematologists and hematologist-oncologists, as well as pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with beta-thalassemia.
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of β-thalassemia, with a forward-looking perspective on how new and novel agents might impact clinical practice. An overview of β-thalassemia, as well as current and emerging treatment strategies, will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.
Upon completion of this activity, participants should be better able to:
- Understand the pathophysiology of iron overload in β-thalassemia
- Identify patients with iron overload in patients with β-thalassemia
- Apply current guidelines for the management of β-thalassemia
- Assess clinical trial data for safety and efficacy of new and emerging therapies for β-thalassemia
Arun Srivastava, PhD
George H. Kitzman Professor of Genetics
Chief, Division of Cellular and Molecular Therapy
Departments of Pediatrics and Molecular Genetics & Microbiology
University of Florida College of Medicine
Hanny Al-Samkari, MD
Assistant Professor of Medicine
Harvard Medical School
Classical Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Arun Srivastava, PhD
- Grant/Research Support: Aavanti Bio, Kitzman Foundation, National Institutes of Health, Pfizer, Sarepta Therapeutics
- Consultant: AgeX Therapeutics, Passage Bio
- Stock/Shareholder: Lacerta Therapeutics
Hanny Al-Samkari, MD
- Grant/Research Support: Agios Pharmaceuticals, Amgen, Dova/Sobi
- Consultant: Agios, Argenx, Dova/Sobi, Forma Therapeutics, Moderna, Novartis, Rigel Pharmaceuticals
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.